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 MATERNAL AND FETAL OUTCOME IN  
JAUNDICE COMPLICATING PREGNANCY 
ABSTRACT 
Aim: 
To evaluate the maternal and fetal outcome in patients with jaundice 
complicating pregnancy in a tertiary care hospital. 
 
Methods:  
The observational study was conducted in Government Thanjavur 
Medical College, Thanjavur, OBG department, Tamil Nadu, India. All 
Antenatal women with jaundice complicating pregnancy cases during one year 
period From August 2016 to July 2017.Different parameters including age, 
parity, gestational age, booking status, mode of delivery, maternal 
complications, Perinatal outcome in terms of birth weight, perinatal morbidity 
and mortality were studied. 
 
Results:  
Total cases of jaundice complicating pregnancy admitted were 65. 
Incidence of jaundice during pregnancy was 0.4 /1000 deliveries. Total 
 primigravida 61.5% and multigravida38.5%.Of this 55.9% delivered by LSCS 
and 45.24% delivered vaginally. Term babies were 44,preterm were 15.And 
50.8%were male and 49.2% were female.Maternal complication rate24.61% 
was with 8 case of maternal death. Live births were 91.5% and 7.6% 
diagnosed as IUD 
 
Conclusion: 
 Jaundice complicating pregnancy is associated with increased maternal 
mortality and morbidity in developing countries like India and significant role 
in maternal and fetal outcome.Thus it becomes necessary to create more 
awareness about the importance of regular antenatal care, health education, 
early diagnosis and appropriate timely treatment to ameliorate many cases and 
to bring out a satisfactory maternal and fetal outcome. 
 
Keywords: 
Jaundice complicating pregnancy, maternal outcome and fetal outcome. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 
 
The incidence of jaundice in India varies from 0.4 to 
0.9/1000 deliveries. Jaundice in pregnancy carries a grave 
prognosis for both the mother and the fetus, and is responsible 
for 10% of maternal deaths. Liver disease in pregnancy is an 
important medical disorder seen more often in developing 
countries than in developed ones. The present study analyzes 
the causes and the fetomaternal outcome in pregnancies 
affected with jaundice. Abnormal liver test results are obtained 
in 3% to 5% of pregnancies because of many potential causes 
and the clinical outcomes ranges from self-limiting to rapidly 
fatal. 
The main causes for abnormal liver tests in pregnant 
patients are: 
(1) Pregnancy-related liver disease. These are the common 
reasons   for abnormal liver function tests in pregnancy. Five 
liver diseases unique to pregnancy includes the following - 
(i) Hyperemesis gravidarum (HG) 
 (ii) Intrahepatic cholestasis of pregnancy (ICP) 
(iii) Preeclampsia 
(iv) Hemolysis elevated liver enzymes, and low platelets 
(HELLP) 
(v) Acute fatty liver of pregnancy (AFLP). 
(2) Newly acquired liver diseases like acute viral hepatitis, drug 
induced liver injury or gallstones 
(3) Preexisting chronic liver disease such as cholestatic liver 
disease, autoimmune hepatitis, Wilson disease, and chronic 
viral hepatitis. 
(4) Physiologic changes in pregnancy - Abnormal liver function 
test due to physiological changes in pregnancy without liver 
dysfunction have a unique pattern. 
The common maternal complications encountered are 
Encephalopathy, Disseminated intravascular coagulation , 
Renal failure, Shock, Postpartum hemorrhage, Pyrexia and also 
Death. Elevated level of serum bilirubin causes vasoconstrictive 
effect on the placental vessels and cardiotoxic effect resulting in 
fetal asphyxia and intrauterine death. Also elevated bilirubin 
 produce cellular effect which stimulates uterine contractility 
and sensitizes myometrium to oxytocin resulting in preterm 
labour. 
High maternal mortality and morbidity in our country are 
due to many factors like Poor hygiene, inadequate sanitation, 
malnutrition, prevalence of anemia, delay in seeking medical 
advice, lack of awareness and delay in referral to the higher 
centers. Many patients are brought in moribund condition to 
the hospital at admission itself and hence they do not respond 
to treatment. 
The prevalence of viral hepatitis in pregnancy can be 
reduced by creating public awareness, proper sanitation 
facilities, safe drinking water and immunization against viral 
hepatitis, improved antenatal care for early detection and well 
equipped hospitals for intensive care. Thereby, mortality and 
morbidity of jaundice complicating pregnancy can be decreased. 
 The aim of this study is to identify the various etiologies 
and distribution of jaundice with reference to age, parity and 
trimesters and also to determine the fetomaternal outcome 
among the pregnant women affected by jaundice treated at 
GOVERNMENT RAJA MIRASDAR HOSPITAL, THANJAVUR. 
 
HISTORY 
 
Jaundice was once called the "morbus regius" with a belief 
that only the touch of a king could cure it. Jaune in French 
means yellow from which the word jaundice was derived. 
Before 400 B.C Hippocrates has written about the yellow 
discoloration in association with fever. Hippocratic physicians 
have treated liver disease and night blindness with raw ox liver 
soaked in honey. In 1724 Cotton Mather has stated that 
―Morbus Regius, or The Royal Disease; because it brings with it 
the Colour of Gold unto them that have it‖. 
In 1864, Stadeler coined the term bilirubin. From 1862 
Friedrich Theodor Frerichs is called as the father of modern liver 
 pathology following his publication ―Klinik 
derLeberkrankheiten‖ in the year 1858. 
 
 
Friedrich Theodor Frerichs 
 
 
ANATOMY OF LIVER 
 
Liver is the largest exocrine gland in the body weighing 
about 1.5 kg in an average adult weighing about 70kg. This is 
located in the right hypochondrium and a part of epigastric 
region. 
Liver is attached to the anterior abdominal wall and the 
diaphragm by four distinctive ligaments: 
(1) Coronary ligament which connects the posterior surface 
of the right hepatic lobe to the diaphragm with a superior and 
an inferior layer between that lies in the bare area of the liver. 
 (2) Right triangular ligament which is formed by fusion of 
the superior and inferior layers of the coronary ligament. 
(3) Left triangular ligament which connects the posterior 
surface of the left lobe of the liver to the diaphragm 
(4) Falciform ligament which extends from the diaphragm 
and anterior wall above the level of the umbilicus to the surface 
of the liver, where it divides the left hepatic lobe into the left 
lateral and left medial segments 
Liver segment is divided into eight segments. COUINAUD 
coined a system for liver segmental nomenclature (8 segments). 
Liver is divided into segments by longitudinal planes drawn 
through each hepatic vein to the vena cava and a transverse e 
level of the main portal bifurcation.Cantlie’s line marks the 
course of the middle hepatic vein. 
 
 
 
 
 
  
 
 
 
 
BLOOD SUPPLY 
 
The two sources that supply blood to the liver are Hepatic 
artery and portal vein. Hepatic artery is a branch from celiac 
trunk of aorta . Portal vein is formed by the confluence of the 
superior mesenteric vein and the splenic vein at the level of the 
 second lumbar vertebra behind the head of pancreas. It 
supplies about 75% of the total liver blood supply by volume 
.Blood exits the liver via the central vein accounting for 
25% of cardiac output. Blood flow into the liver is controlled by 
number of factors like Muscular sphincters, autonomic nervous 
system, circulating hormones, bile salts, and metabolites.  
 
VENOUS DRAINAGE 
 
Majority of the venous drainage of the liver occurs through 
three hepatic veins .Right hepatic vein drains the segments 6, 7, 
8 and enters directly into the vena cava. Middle hepatic vein 
drains segments 5 and inferior part of segment 4. Left hepatic 
vein drains the segments 2, 3 and superior part of 4. 
  
MICROANATOMY 
 
Liver is composed of hexagonal shaped units tiny 
hexagonal or pentagonal cylinder of about 2x1 mm. These form 
the anatomical units of the liver. A tributary of hepatic vein 
 extends through these anatomical units called interlobular vein 
(central vein). 
Around this central vein hepatic cells are radiating 
outward. On the outer corners of each lobule branch of portal 
vein, a branch of hepatic artery and an interlobular arranged. 
Three adjoining drainage of bile into bile ductules of portal 
triad. 
 
  
PORTAL TRIAD 
 
Branches of portal vein, hepatic artery and the biliary 
ducts bound together in the perivascular fibrous capsule to 
form portal triad. Hepatocytes are arranged in plates joined with 
tight junctions and the apical membrane forms the biliary 
caniculi 
 Hepatocytes are segregated from the blood-filled sinusoids 
by fenestrated endothelial cells without a basement membrane, 
and by a loose connective tissue layer known as the space of 
Disse.  
 
HEPATIC STELLATE CELLS 
 
These are Star shaped cells that reside in the space of 
Disse. It helps to Store lipids particularly vitamin A. 
Inflammatory cytokines cause activation, which involves 
the loss of stores of vitamin A and a dramatic upregulation in 
the production of extracellular matrix materials, such as 
collagen. When collagen is deposited in the space of Disse it 
impairs hepatic function. 
 
KUPFFER CELLS 
 
Kupffer cells belong to macrophage lineage. The sinusoids 
are lined by kupffer cells which clear the cellular debris and 
other particulate material and to some extent bacteria that 
enters the portal triad. 
 They express cell-surface receptors for altered proteins. Fc 
immunoglobulin receptors used to internalize foreign proteins or 
microorganisms that have been coated with host antibodies. 
 
BILIARY SYSTEM 
 
Gallbladder is a biliary reservoir that lies against the 
inferior surface of segments IV and V of the liver, usually 
making an impression against it. A peritoneal layer covers most 
of the gallbladder except for the portion adherent to the liver. 
The size is variable, but usually about 10 cm long and 3 to 5 cm 
wide. Gallbladder is composed of a fundus, body, infundibulum, 
and neck. Ultimately empties into the cystic duct 
 
BIOCHEMICAL FUNCTIONS OF LIVER 
 
1. Storage of substances like protein, glycogen, vitamins and 
folic acid. 
2. Synthesis of plasma proteins, glycogen, phospholipids, bile 
acids and heparin. 
 3. Secretion of bile acids and bile pigments into the bile. 
4. Metabolism of carbohydrate, protein and fat. 
5. Excretion of heavy metals, hormones, cholesterol and bile 
pigments. 
6. Detoxification of ingested drugs. 
7. In fetal life the liver produces RBC and WBC. 
8. Kupffer cells acts as body defence. 
9. Thyroxine is converted into triiodothyronin and also 
participates in the    activation of vitamin D. 
10. Converts toxic substances into nontoxic substances e.g., 
benzoic acid is converted into hippuric acid by conjugation 
with glycine. Ammonia is converted to urea. 
 
PRODUCTION AND METABOLISM OF BILIRUBIN: 
SOURCE OF BILIRUBIN: 
Mainly 80% is from senescent RBC and about 15 -20 % 
from ineffective erythropoiesis. Metabolism of haem containing 
protein can be divide into three phases: 
(i) Hepatic uptake 
 (ii) Conjugation 
(iii) Excretion into bile (rate limiting step) 
UPTAKE: 
Unconjugated bilirubin bound to albumin enters liver and 
the complex dissociates. Non-polar bilirubin enters the 
hepatocyte by diffusion or transport across plasma membrane. 
It binds to cytoplasmic anion binding protein ligandin 
glutathione-s-transferase and prevents efflux of bilirubin back 
into plasma. 
CONJUGATION: 
 
Unconjugated bilirubin is water insoluble. Hence gets 
conjugated to glucuronic acid forming bilirubin glucoronide , 
which is water-soluble.Conjugation occurs in endoplasmic 
reticulam. Catalysed by glucuronyl transferase in two step 
reaction. 
EXCRETION: 
 
Conjugated bilirubin is water soluble and is secreted by 
the hepatocytes into the biliary canaliculi. It is converted to 
 stercobilinogen by bacteria in the gut and Oxidized to 
stercobilin which is colored. Excreted in feces. Some stercobilin 
may be re-adsorbed by the gut and re-excreted by either the 
liver or kidney 
Causes of Unconjugated hyperbilirubinaemia: 
 
1) Increased bilirubin formation e.g., Haemolysis, Ineffective 
erythropoiesis, Blood transfusion and Haematoma.       
2) Decreased bilirubin uptake by hepatocyte e.g., Drugs like 
Rifampicin, Gilbert’s syndrome 
3) Deficit in conjugation - Gilbert’s syndrome, Crigler Najjar, 
Drugs. 
Causes of Unconjugated hyperbilirubinaemia: 
 
1) Dubin-Johnson syndrome, Rotor’s syndrome 
2) Hepatocellular dysfunction 
3) Hepatic disorder with prominent cholestasis 
4) Biliary duct obstruction. 
 
 
 
 
  
 
PREHEPATIC JAUNDICE 
Prehepatic jaundice results from excessive RBC lysis as in 
haemolytic anaemia. Unconjugated bilirubin level is increased. 
 
 
 
 
  
 
HEPATIC JAUNDICE 
As a result of liver dysfunction there is impairment of 
uptake , conjugation and secretion of bilirubin , hence both 
direct and indirect bilirubin level increases. 
 
 
 
 
 
 
 
  
 
 
POSTHEPATIC JAUNDICE 
When there is obstruction to biliary tree, the conjugated 
biliribin level gets elevated. 
 
 
 
 
 
 
  
 
 
 
 
 
CAUSES 
 
JAUNDICE 
 
BILIRUBIN 
IN SERUM 
 
BILIRUBIN 
IN URINE 
 
UBG 
IN 
URINE 
 
UBG IN 
FAECES 
 
Prehepatic 
 
Haemolytic 
 
↑ indirect 
 
No 
↑ ↑ 
 
Hepatic 
 
Hepatic 
 
↑Both 
direct 
and 
indirect 
 
Yes 
↓ ↓ 
 
Posthepatic 
 
Obstructive 
↑Direct Yes No No 
 
 
 
 
 
 
 
 
 
  
PHYSIOLOGIC CHANGES IN LIVER FUNCTION TESTS 
DURING 
PREGNANCY 
 
 
Liver Test Results 
 
Physiologic Changes Compared 
With Normal Range 
 
Increased 
 
Alkaline phosphatase , 
fibrinogen, 
fetoprotein, white 
blood cell, ceruloplasmin, 
cholesterol , 
alpha or/and 
beta globulins, triglycerides 
 
Unchanged 
 
 
Aminotransferases, prothrombin 
time 
 
Decreased  
 
 
Bilirubin, g-globulin, hemoglobin 
 
 
  
DISEASE PRESENTATION AND THE TIMING OF ONSET DURING 
PREGNANCY 
 
Disease 
Categories 
 
First Trimester  Second 
Trimester 
 
Third Trimester 
 
Preexisting Liver 
Diseases 
Chronic hepatitis B or C, autoimmune 
hepatitis, primary sclerosing cholangitis, 
Wilson disease, primary biliary cirrhosis, cirrhosis 
Newly Acquired 
Liver 
Diseases 
Viral hepatitis, gallstones, drugs, sepsis, 
Budd-Chiari syndrome 
Diseases Related 
to Pregnancy 
Hyperemesis 
gravidarum 
 
Intrahepatic 
cholestasis 
 
ICP, AFLP , 
preeclampsia, 
HELLP 
 
 
 
  
 
 
AIMS 
AND 
OBJECTIVES 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES OF OUR STUDY: 
 
                            - To analyze the maternal outcome in terms 
of mode of termination of pregnancy, 
maternal complications andmortality of 
jaundice complicating pregnancy. 
- To identify the relation of maternal    
morbiditymortality in relation to admission 
serum   bilirubin level. 
- To assess fetal outcome by perinatal 
mortality and morbidity. 
 - To identify the various etiologies and   distribution of jaundice 
with reference to age, parity and trimesters. 
   Inclusion criteria:  Pregnant women affected by elevated liver                                
parameters and viral positivity treated in 
Government Raja Mirasudar Hospital, 
Thanjavur. 
  Exclusion criteria: Normal antenatal women. 
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LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
Herman Aldercreutz et al.,(1965) studied the clinical 
symptoms, liver function tests and ultrastructural alterations of 
the liver during pregnancy and found out that the 
ultrastructural alterations in recurrent jaundice of pregnancy 
seem to be rather nonspecific, since similar structural changes 
have been observed in biliary stasis of extra hepatic origin and 
in infectious or toxic liver diseases.1 
British medical journal (1967) discussed the association 
between jaundice after administration of an oral contraceptive 
and the intrahepatic cholestasis of pregnancy. About 100 cases 
of jaundice from oral contraceptives have been reported.In the 
largest series, 50 Chilean patients, the clinical, biochemical, 
and microscopical findings bore a strong resemblance to those 
of cholestatic jaundice of pregnancy. Forty of these 50 patients 
had previously been pregnant, during which 17 had suffered 
jaundice and pruritus and ten late pruritus only.2 
Ireneusz Roszkowski et al., (1968) studied 49 cases of 
jaundice in pregnancy, in which he had found out that the 
 presence of jaundice, regardless of origin, in pregnancy leads to 
a rise in acute intense contractions which shorten labor 
duration but increase the threat to the fetus. The course of the 
idiopathic jaundice in pregnancy is mild and the clinical 
symptoms disappear a few days after delivery. Delivery in cases 
of jaundice in pregnancy occurs at term and the average weight 
and length of the infants do not differ from those observed in 
normal deliveries. In idiopathic jaundice in pregnancy, 
complicated by pyelonephritis, premature deliveries are due to 
urinary tract infection rather than to the coexisting jaundice. 
Interrelationships between the duration of labor and the 
increased enzyme activity (serum transaminase, alkaline 
phosphatase) or increased bilirubin levels were not detected.3 
Lunzer.,(1989) discussed about the occurrence of 
hepatobiliary disease with or without jaundice during 
pregnancy, and stated that management of liver disorders 
unique to pregnancy and hepatobiliary disease in general have 
resulted in a significant improvement in the outcome for both 
mother and fetus. Certain disorders such as acute fatty liver of 
 pregnancy and hepatic haemorrhage associated with toxaemia 
should be considered medical emergencies and delay in 
diagnosis of these conditions will probably adversely affect 
maternal and fetal outcome. 
Thomas Murphy Goodwin., (2002) studied the strong 
evidence of HCG and estrogen linked with the cause of nausea 
and vomiting during pregnancy, and stated that the response of 
a pregnant woman to the primary stimulus to nausea and 
vomiting of pregnancy appears to depend on her susceptibility 
mediated by vestibular, gastrointestinal, olfactory, and 
behavioral pathways.4 
Emily S. Gurley et al., (2012) estimated the population-
based incidence of maternal and neonatal mortality associated 
with hepatitis E virus in Bangladesh, and found that 19% to 
25% of all maternal deaths and 7% to 13% of all neonatal 
deaths in Bangladesh were associated with jaundice in pregnant 
women.5 
 KF Vandraas et al.,(2013)  studied the association between 
hyperemesis gravidarum(HG) and birth outcomes in Norway 
which revealed no associations between HG and adverse 
pregnancy outcomes were observed in crude analyses, except 
for VPTB, Inverse associations were observed between HG and 
VPTB, Sub-analyses showed no associations between HG and 
perinatal death. It was concluded as HG was associated with 
slight reductions in birthweight and gestational age.6 
AshishGoel et al., (2014) studied the Pregnancy-related 
liver disorders which had accounted for 8% of all maternal 
deaths at their center from 1999 to 2011. Of the three 
pregnancy-related liver disorders (acute fatty liver of pregnancy 
(AFLP), HELLP (Hemolysis, elevated liver enzymes, low platelets) 
syndrome and pre eclamptic liver dysfunction, which can lead 
to adverse maternal and fetal outcome, AFLP is most typically 
under - diagnosed. Risk of maternal death can be minimized by 
timely recognition and early/aggressive multi-specialty 
management of these conditions.7 
 Kalyani Singh.,  (2016) studied jaundice in pregnancy and 
found out that viral hepatitis was the most common cause of 
the jaundice and concluded that 1 in every 1000 pregnancies in 
India, is associated with adverse maternal and foetal outcome 
because of jaundice complicating pregnancy.8 
Cihan Kaya et al., (2016)  discussed about the incidence 
and risk factors of hyperemesis gravidarum and concluded that 
Non-pharmacological treatment may be offered as the first-line 
treatment, and Patients with electrolyte imbalance and 
ketonuria might require medical treatment or hospitalization.9 
NipunVerma et al., (2017) reported that 25-year-old, 31-
week pregnant woman presented with jaundice for 5 days and 
altered sensorium for 2 days with features of both viral acute 
liver failure (ALF) and tropical infections mimicking ALF, 
including hyperbilirubinemia, coagulopathy, anemia, 
thrombocytopenia, intravascular hemolysis, and 
hepatosplenomegaly. Etiological workup revealed rare 
coinfection of hepatitis E and scrub typhus which lead to poor 
 fetal outcome, which resulted in stillbirth and grave maternal 
prognosis.10 
Anthony Laku Stephen Kirbak et al., (2017) conducted a 
cross-sectional study among pregnant women attending 
antenatal clinic for hepatitis B infection and documented that 
the prevalence of Hepatitis B surface antigen (HBsAg) among 
pregnant women attending ANC in Juba was 11%.11 
Namrata Kumar et al., (2017) found out that Hepatitis E 
positivity was significantly associated with maternal mortality, 
intrauterine demise with prematurity, and premature rupture of 
membranes was the most common fetal complication, and also 
tabulated the distribution of different types of jaundice where 
Feto  maternal outcomes were significantly better with HBV, 
HCV, and HAV hepatitis compared with HEV infection.12 
 
Liver disease complicating pregnancy is divided into 3 
general categories. First category includes those specifically 
related to the pregnancy such as acute fatty liver of 
pregnancy,hyperemesis gravidarum,intra hepatic 
 cholestasis,HELLP syndrome. Second category includes acute 
hepatic disorders that are coincidental to pregnancy such as 
acute viral hepatitis,gall stones. Third category includes chronic 
liver diseases. Worldwide,most common cause of jaundice is 
viral hepatitis.3 
 
 
LIVER DISEASES RELATED TO PREGNANCY 
HYPEREMESIS GRAVIDARUM 
HG is defined as intractable nausea and vomiting during 
the first trimester of pregnancy. Most severe illness in the 
spectrum of vomiting in pregnancy.13In 0.3% of pregnancies it 
may lead to dehydration and electrolyte imbalance. But usually 
resolves by 16 to 18 weeks. In up to 10% of women, symptoms 
continues throughout pregnancy and resolve only with delivery 
of the fetus.14,15 
The mechanism for Hyperemesis remains unclear. 
Proposed mechanisms include hormonal imbalance with 
elevated levels of human chorionic gonadotropin (HCG) and 
estrogen and decreased levels of prolactin, along with 
 overactivity of the hypothalamic-pituitary-adrenal axis.16,17High 
level of HCG stimulates the thyroid gland and upregulate the 
secretary processes of the upper gastrointestinal tract.16 High 
levels of TNF alpha, IgG, IgM, C3, C4, natural killer cells, and 
extrathymic T cells observed in these women suggest that 
cytokine, T cell–mediated immune reactivation, immunoglobulin 
and complement play an important role in Hyperemesis.18,19 
Risk factors includes – 
                                    a. Molar pregnancy 
                                    b. Multiple pregnancies 
    c. Preexisting diabetes or 
hyperthyroidism 
d. Psychiatric disorders 
Hyperemesis is a clinical diagnosis and based on exclusion 
of other underlying or newly acquired liver diseases.14 An 
abnormal LFT is seen in up to 50% of cases.20Transaminases 
are usually 2 to10 fold elevated. Rarely can be up to 20 times 
the normal with mild jaundice. 
 HG resolves in most patients with the replacement of 
electrolytes and glucose, rehydration, and nutritional support. 
Parenteral hydrocortisone may lead to rapid resolution in severe 
cases, with slow improvement. Serious complications like 
malnutrition, esophageal tear, 21, 22 hyperthyroidism, 15or even 
Wernicke encephalopathy caused by vitamin B12 deficiency can 
occur rarely.23 
INTRAHEPATIC CHOLESTASIS OF PREGNANCY 
 
Elevated bile acid (BA) levels during the late second or 
third trimester of pregnancy, with resolution after delivery 
associated with pruritus. Risk factors for ICP are advancing 
maternal age, twin pregnancies, multiparity and oral 
contraceptive use. Prevalence is 1 in 1000 to 1 in 10000. 
Cause of ICP is multifactorial, involving genetic, hormonal, 
and exogenous factors. Sex hormones can cause cholestatic 
effects through inhibition of the hepatocellular bile salt export 
pump (Bsep).24Also, pregnancy is associated with an abnormal 
metabolic response with impaired sulfation.  
 The hepatic transport systems for biliary excretion are 
affected and saturated by the large amount of sulfated 
progesterone metabolites.25,26Genetic studies suggests that at 
least 10 different multidrug resistance–associated protein (MDR) 
3 mutations have been identified in progressive familial 
intrahepatic cholestasis.27 
Pruritus usually starts during weeks 25 to 32 of pregnancy 
and resolves after delivery, excoriations caused by scratching 
are often noted on physical examination. Serum abnormalities 
detected 4 weeks after the onset of pruritus.28 Early and specific 
abnormality is the elevation of serum total bilirubin acid level 
and it is usually less than 5 mg/dL. Fetal morbidity and 
mortality are correlated 
with maternal BA levels.  
Jaundice occurs in 10%to25%of patients and some may 
have diarrhea. Clinical improvement in ICP with the 
administration of cholestyramine,29 dexamethasone,30 and S-
adenosyl-L-methionine. 
 Antihistamines,benzodiazepines, phenobarbital, and epomediol 
have no benefit.31 
UDCA is the treatment of choice for ICP.Close monitoring 
and early delivery after confirming fetal lung maturity may 
bethe best way to prevent sudden antenatal death. Glantz and 
colleagues 35havesuggested using maternal BA levels of 40 
mmol/L as a threshold for early delivery. 
 
 
 
 
 
 
 
 
 
 
  
 
 
HELLP SYNDROME 
HELLP syndrome is a multisystem disorder characterized 
by hemolysis, elevated levels of liver enzymes, and low platelet 
counts with or without preeclampsia.The prevalence is 
estimated to be 0.6% of deliveries.21 Risk factors are advanced 
maternal age, Whites and multiparity. It occurs in the third 
trimester in two-thirds of the Patients. Microangiopathic 
hemolytic anemia is associated with vascular endothelial injury, 
fibrin deposition in blood vessels, and platelet activation with 
platelet consumption. It is the hallmark of the syndrome but is 
not specific to this entity. 
Periportal or focal parenchymal necrosis with hyaline 
deposition of fibrin material in the sinusoids is the 
characteristic histopathological finding.33,34 Clinical symptoms 
includes epigastric or right upper quadrant pain, malaise, 
headache, nausea, and vomiting. 
 On physical examination, hypertension, generalized 
edema, and gain are common signs. 
Three laboratory criteria: 
 Thrombocytopenia 
 Elevated aminotransferase 
levels 
 Hemolysis. Several different 
classifications have been 
proposed. 
Platelet count less than 100,000/mm3, aspartate 
aminotransferase levels greater than 70 U/L, and L-lactate 
dehydrogenase (LDH) levels greater than or equal to 600 U/L 
are helpful to make the diagnosis. The Mississippi classification 
is based on the degree of thrombocytopenia and the elevation of 
transaminase and LDH levels. Mississippi classification is for 
assessing the severity of the pathologic process. Frequent 
complications are disseminated intravascular coagulopathy 
(30%), abruptio placentae (16%), acute kidney injury (7.7%), 
aspiration 
 pneumonia (7%), pulmonary edema (6%), acute respiratory 
distress syndrome, cardiopulmonary arrest (4%), cerebral 
hemorrhage (1.2%), and retinal detachment (0.9%). Rarely, 
severe ascites, subcapsular hematoma, hepatic failure, and 
hepatic rupture can occur (0.015%).35,36 
Proteinuria is not required to make the diagnosis. 
Computed tomography (CT) may show subcapsular hematomas, 
intraparenchymal hemorrhage, hepatic rupture, or infarction. 
Transfer to a tertiary care center is advocated. If the pregnant 
woman is at or beyond 34 weeks’ gestation or if there is any 
evidence of multiorgan dysfunction or severe complication, 
immediate induction of labor is recommended. Close monitoring 
of the mother should be continued after delivery also. 
Most laboratory values normalize in 48 hours after delivery 
of the fetus. Causes of perinatal mortality include abruptio 
placenta,asphyxia, and prematurity. Subsequent pregnancies in 
patients with HELLP syndrome carry a high risk of 
complications including recurrent HELLP. 37, 38 
 ACUTE FATTY LIVER OF PREGNANCY 
 
AFLP occurs in 1 in 7000 to 16000 pregnancies.39,40 
Associated with microvesicular fatty infiltration of the liver, 
hepatic failure, andencephalopathy. It occurs commonly in the 
third trimester of pregnancy.Deficiencies of the enzymes of 
mitochondrial fatty acid beta oxidation (FAO)results in fatty 
infiltration of the liver. The most commonly enzyme deficiency 
islong-chain 2-hydroxyacyl-CoA dehydrogenase (LCHAD) 
deficiency. The defect isin the alpha subunit of the 
mitochondrial protein is associated with G1528C orE474Q 
mutations.41,42Natarajan and colleagues43demonstrated that 
placentalmitochondrial function is compromised in AFLP, which 
may lead to free radicalproduction and accumulation of fatty 
acids in the placenta, resulting in maternalhepatocyte stress 
and mitochondrial dysfunction leading to acute liver failure.40% 
to 50% of patients with AFLP are nulliparous with an increased 
incidence intwin pregnancies.44Symptoms includes anorexia, 
nausea, emesis, malaise,fatigue, and headache. 
 On physical examination, the patient may have jaundice, 
hypertension, edema, and hepatic encephalopathy. Serum 
amino transferase levels vary from 300 to 500 U/L. The total 
bilirubin concentration is usually less than 5 mg/dL. Other 
laboratory abnormalities include anemia, leukocytosis, normal 
or low platelet counts, coagulopathy with or without DIC, 
hypoalbuminemia, hypoglycemia,and acute kidney injury. 
Management includes hospitalization for stabilization of 
hypertension and DIC, seizure prophylaxis. Fetal monitoring 
followed by immediate delivery of the fetus or termination of the 
pregnancy along with intensive support. The aminotransferase 
levels and encephalopathy improve within 72 hours of delivery. 
Most recover in 1 to 4 weeks post partum. 
Maternal mortality is 3% to 12% and fetal mortality is 15% 
to 66%. The strong association of AFLP with LCHAD deficiency 
in the fetus suggests a necessity of neonatal testing for 
enzymatic defects of FAO. Women who are carriers of the 
LCHAD mutation have an increased risk of recurrence of AFLP 
in 20%to 70%of pregnancies. 
 Elevated level of serum bilirubin causes vasoconstrictive 
effect on the placental vessels and cardiotoxic effect resulting in 
fetal asphyxia and intrauterine death. Also elevated bilirubin 
produce cellular effect which stimulates uterine contractility 
and sensitizes myometrium to oxytocin resulting in preterm 
labour. 
The fetomaternal complications of jaundice in pregnancy 
are not only due to jaundice alone but largely due to the 
underlying causes of these conditions. Thus the management 
depends on the underlying cause. Careful examination and 
vigilance is required to detect the early sign of hepatic 
dysfunction and to differentiate these from the physiological 
changes during pregnancy. Management of jaundice in 
pregnancy requires a combined effort of physician, 
gastroenterologist, obstetrician and on rare occasions, a liver 
transplant team.  
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MATERIALS AND METHODS 
Sixty five women with jaundice complicating pregnancy 
admitted and treated at Government Raja Mirasudar 
Hospital,Thanjavur from August 2016 to July 2017 were 
studied. 
 A detailed history including patient’s age, socioeconomic 
status , booking ,and details of menstrual history to arrive 
at the expected date of delivery was obtained. 
 Patients were enquired in detail about their complaints 
and duration like nausea, vomiting , pruritus , anorexia , 
yellow coloured urine, pale stools, edema legs , bleeding 
tendency , joint pain , fever and others. 
 Past history of jaundice especially in previous pregnancy 
and history of blood transfusion were elicited. 
 systemic and obstetric examinations were carried out. 
 Investigations included liver function tests, serum 
billirubin, SGOT, SGPT, alkaline phosphatase, Viral 
markers, prothrombin time (PT), partial thromboplastin 
 time (PTT), bleeding time (BT), clotting time (CT), platelet 
count and ultrasound abdomen were carried out as and 
when required. 
 HIV screening was done in all patients. 
 Medical gastroenterologist opinion was obtained for all 
cases. 
 Labour was closely monitored. Jaundice perse was not an 
indication for cesarean section. Vaginal delivery with close 
monitoring was preferred and cesarean sections were done 
only for obstetric indication. After crossmatching fresh 
blood was kept ready as alteration in coagulation profile 
wasexpected in jaundice complicating pregnancy. 
 Atonicity was managed with oxytocin drip, injection 
methergin and injection15 methyl PGF2α. 
 Patients were kept in the labour ward for close 
observation. Clotting time wasrepeated hourly if it was 
prolonged till it becomes normal. 
 Soon after delivery all babies were assessed by 
paediatrician. Alive or dead , sex , gestational age at birth , 
 weight , apgar score and presence or absence of any 
congenital anomalies were looked for and noted. As per 
paediatrician opinion sick babies were admitted in preterm 
ward for intensive care. 
 Of the 65 women, 26  had viral hepatitis, 2AFLP, 17 
HELLP , 1cholestatic , 10 HELLP with severe pre 
eclampsia, 1 HELLP with AP eclampsia, 1 HELLP with 
acute kidney injury, 2 HELLP with viral infection, 3 
Hyperemesis gravidarum . 
 The maternal outcome was noted in terms of the mode of 
delivery, maternal complications and maternal 
mortality.The relation of maternal morbidity and mortality 
to the admission serum bilirubin level was analyzed 
 To identify the various etiologies and distribution of 
jaundice with reference to age, parity and trimesters. 
 Fetal outcome was assessed by perinatal morbidity and 
mortality 
 
 
  
 
 
 
 
OBSERVATIONS 
AND RESULT 
 
 
 
 
  
OBSERVATIONS AND RESULT 
In India the incidence of jaundice varies from 0.4 to 
0.9/1000 deliveries. According to this study the incidence of 
jaundice is 4/1000 deliveries. Kamalajayaram and Rama Devi 
35reported 0.4/1000 incidence. Singh et al 34 reported 
1.03/1000 incidence while. Of the 65 women studied 56.9% 
were in 21 to 25 yrs of age (TABLE 1). Mean age is 24 yrs. 
About 61.5% were primi and 26.2% were Multi gravida (TABLE 
4). 87.6% were in third third trimester (TABLE 3). 
Etiologies for jaundice 
Of the 65 women, 28 had viral hepatitis (43 %), 2 AFLP 
(3%), 17 HELLP (26.6 %), 1 cholestatic (1.5%), 3 
hyperemesis(4.6%),1 haemolytic anaemia (1.5%)(TABLE 9). 
Among the 28 viral hepatitis 89.2% was due to hepatitis B, 
hepatitis C7.3% and hepatitis A 3.1%, 1 death due to viral 
hepatitice. 
 
  
Relation with serum bilirubin level 
Maternal mortality was directly related to the level of 
serum bilirubin as shown in (Table 19). 57 women were 
discharged in improved condition – 3 undelivered, 59 
deliveredInitial serum bilirubin level of > 13 lead to 50% 
mortality. About 33.8% of women had an initial serum bilirubin 
level of about 5 – 10 mg / dl. 
Pregnancy outcome 
Among the 65 women studied 59 women got delivered 
(90.7%). 6 womenremained undelivered (TABLE 5). Of these 65 
women, 4 expired due to HELLP,2 AFLP,1 AKI and 1 due to viral 
hepatitis.  . Others improved and were discharged. Of the59 
women delivered vaginal delivery (44.9%) and LSCS (55.9%). 
8 cases of Atonic PPH was observed. 2 were following 
vaginal delivery and 6 following LSCS. . 
Maternal outcome 
6.1%developed hepatic encephalopathy, 28% ARF, 22% 
atonic PPH, 17% abruption and 5% DIC. (Table 23) 
  
Cause of death 
In our study, eight women expired. HELLP (50%) was the 
cause in 4 out of 8 women who died. Two women died of 
AFLP(25%) and one due to AKI (12.5%), one due to VIRAL 
HEPATITIS (12.5%) (Table 26). 
 
 
Fetal outcome 
0f the 59 women delivered, one was a twin delivery by 
labour natural survived. 91.5% born alive and 8.5 % were 
intrauterine death (Table 13). 50.8% were male babies and 
49.2% were female babies (Table 14).  
 
 
 
  
 
 
 ANALYSIS 
 
 
 
 
 
 
 
             Table 1: Age distribution of the subjects in the study population 
 
S.No Age (in years) Number (n) Frequency (%) 
1 ≤20 7 10.77 
2 21-25 37 56.93 
3 26-30 15 23.08 
4 31-35 5 7.69 
5 >35 1 1.53 
 
 
 
Among the studied population group  (56.9%) belongs to 
the age group of 21-25 years,and the least common age group 
affected by Jaundice is >35 years of age . 
 
 
 
 
Figure.1: Age distribution of the subjects in the study population. 
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 Table 2: Statistical data for the age analysis of the subjects in the study population 
 
 
S.No Parameter Value 
1 Mean 24.7 years 
2 Median 24 years 
3 Mode 24 years 
4 Standard deviation 4.11 
5 Variance 16.9 
6 Range 19 to 43 
 
 
According our study the mean age  affected by  jaundice is 
24.7 years and thevariance is 16.9,the occurrence ranges from 
19 -43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 3: Trimester distribution of the subjects in the study sample 
 
The occurrence of jaundice was high during third 
trimester. 87.6% were in thirdtrimester, lowest incidence of 
jaundice were seen in second trimester which was around 3.1% 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
I 
6 9.3 9.3 9.3 
II 2 3.1 3.1 12.4 
III 57 87.6 87.6 100 
Total  65 100 100  
 
 
 
 
S.No Type of the trimester  Frequency (%) 
1 Trimester I 6 9.3 
2 Trimester II 2 3.1 
3 Trimester III 57 87.6 
  
 
 
 
 
 
 
 
Figure 2: Trimester distribution of the subjects In the study samples 
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 Table 4: Distribution of the type of parity in the study population 
 
S.No Type of parity Number (n) Frequency (%) 
1 Primi 40 61.5 
2 Gravida 2 17 26.2 
3 Gravida 3 5 7.7 
4 Gravida 4 1 1.5 
5 Gravida 5 2 3.1 
 
Of the total 65 women studied, 61.5% were primigravida 
and 26.2% were Multi gravida. 
 
 
 
 
Figure 3: Distribution of the type of parity in the study population. 
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 Table 5:Pregnancy outcome. 
 TOTAL PERCENTAGE(%) 
DELIVERED 59 90.7 
UNDELIVERED 6 9.3 
TOTAL 65  
 
59 out of 65 patients delivered (90.7%). 6 remained 
undelivered.  
 
 
 
 
Figure 4: Pregnancy outcome 
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 Table 6: Statistical data for the gestational age in days of the subjects in the study 
population 
 
S.No Parameter Value 
1 Mean 249.5 days 
2 Median 265 days 
3 Mode 270 days 
4 Standard deviation 43.3 days 
5 Variance 1882  
6 Range 98 to 277 
 
The mean age for occurrence of jaundice is 249.5 days and 
its ranges from98-277 days and the standard deviation is 
43.3days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 7: Distribution of the booking status and reference status of the patients in the study     
Population 
S.No Parameter Number (n) Percentage (%) 
1 
Booking status 
Booked 63 96.9 
Not booked 2 3.1 
2 
Referal 
Referred 60 92.3 
Self 5 7.7 
 
From the 65 population studied, 63 patients 96.6%, were 
booked and only 2 patients (3.1%) were unbooked. In this study 
92.3% of patients refered from various government and private 
hospitals and others are self. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 8: Frequency distribution of mode of delivery done in the study population: 
 
 
S. 
No 
Mode of delivery 
Number 
(n) 
Frequency 
(%) 
1 ABD 1 1.6 
2 Elective LSCS 2 3.3 
3 LSCS 28 47.4 
4 Emergency hysterotomy 1 1.6 
5 Labour natural with episiotomy 23 38.9 
6 RPT LSCS 2 3.6 
7 Spontaneous expulsion 1 1.6 
8 Vacuum  1 1.6 
 
 
From the population studied, the most common mode of 
delivery was by LSCS around 55.9% and 44.9% were delivered 
vaginally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 9: Frequency distribution of diagnosis done in the study population: 
 
S.No Type of diagnosis 
Number 
(n) 
Frequency 
(%) 
1 AFLP 2 3.1 
2 HELLP 17 26.2 
3 HELLP with AKI 1 1.53 
4 HELLP with eclampsia 1 1.53 
5 HELLP with SPE 5 7.7 
6 HELLP with viral infection 2 3.1 
7 HG 2 3.1 
8 HG with wernicks 1 1.53 
9 Hemolytic anemia 1 1.53 
10 Intrahepatic cholestatis 1 1.53 
11 Partial HELLP 1 1.53 
12 Viral infection 26 40 
13 No definitive diagnosis attained 5 7.7 
 
 
 
The most common case for jaundice from our study group 
is viral hepatitis (43.1%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 10: MATURITY OF BABY 
 
59 Babies out of15 were premature.3 out of this 59 babies 
were intrauterine deaths. Inspite of intensive care 2 out of 15 
babies expired. 
 
 
 
 
 
 
 
MATURITY OF 
BABY 
TOTAL PERCENTAGE TOTAL PERCENTAGE 
PRETERM 15 24.3 
TERM 44 70.9 
ABORTUS 3 4.8 
TOTAL 62 100 
  
 
 
Figure 5: MATURITY OF BABY 
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 Table 11: SEX OF THE BABY 
SEX OF THE BABY TOTAL PERCENTAGE 
MALE 30 50.8 
FEMALE 29 49.2 
TOTAL 59  
 
 
 
Figure 6: SEX OF THE BABY 
 
 
From the population studied,(50.8%) delivered male child 
and 29 patients delivered female child it is 49.2%. 
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Table 12: Frequency distribution of neonatal outcome measures in the study population 
 
S. No Parameter Number (n) Percentage (%) 
1 
Term of the baby 
Preterm 15 25.5 
Term 44 74.5 
2 
Birth state of the baby 
Born alive 54 87.2 
Still born 5 8.0 
Aborted 3 4.8 
3 
Sex of the baby 
Female 29 49.2 
Male 30 50.8 
4 
NICU admission 
Yes 15 25.4 
No 44 84.6 
 
Off these 59 patients 44 patients (74.5%) delivered 
termbabies and 15 delivered preterm babies . 87.2% were born 
alive and 8.5% were still born( 3 IUD+ 2 PERINATAL DEATH). 
 
 
 
  
 
Table 13: FETAL OUTCOME 
FETAL OUTCOME TOTAL PERCENTAGE 
BORN ALIVE 54 91.5 
DEATH(IUD+PERINATAL) 5 8.5 
 
0f the 59 delivered, 91.5% born alive and 8.5 % were 
intrauterine death. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: FETAL OUTCOME 
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Table 14:BIRTH WEIGHT 
 
S.No. Baby Weight(Kg) Male Female 
1 <2 7 11 
2 >2.5 - 3 22 18 
3 >3 1 - 
 
 
Total number delivered 59 of this 18 babies were low birth 
weight, 7 are male, and 11 were female. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: BIRTH WEIGHT 
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Table 15:Distribution of frequencies of associated medical disorders in the study 
population 
 
S.No 
Type of the associated medical 
disorders 
Number (n) 
Frequency 
(%) 
1 No associated disorders 39 60 
2 Acute kidney injury 1 1.5 
3 Gestational diabetes mellitus 2 3.1 
4 
Gestational diabetes mellitus with 
gestational hypertension 
2 3.1 
5 Gestational hypertension 12 18.5 
6 
Gestational hypertension with 
severe anemia 
3 4.6 
7 Hypothyroidism 4 6.2 
8 Nephrotic  syndrome 1 1.5 
9 Splenomegaly 4 1.5 
 
The most common complication in the study group was 
Gestational hypertension (18.5%),least common complications 
are nephrotic syndrome and splenomegaly. 
 
 
 
  
 
 
Table 16: Vital signs characteristics in the study population 
 
S.No Parameter Mean 
Standard 
deviation 
Range 
1 Heart rate (in bpm) 82.3 6.4 70 to 110 
2 
Systolic blood 
pressure (mm of Hg) 
122 15.7 100 to 160 
3 
Diastolic blood 
pressure (mm of Hg) 
79.2 10.6 70 to 110 
 
In this study group the mean blood pressure of systolic 
122 mm Hg and diastolic 79.2 mmHg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 17: Distribution of various clinical symptoms in the study population 
 
S.No Parameter Number (n) Percentage (%) 
1 
Icterus 
Absent 43 66.15 
Present (+) 21 32.3 
Present (+++) 1 1.53 
2 
Pallor 
Absent 34 52.3 
Present (+) 30 46.1 
Present (++) 1 1.53 
3 
Pedal edema 
Absent 35 53.8 
Present (+) 20 30.7 
Present (++) 10 15.38 
4 
Urine output 
Normal 47 72.3 
Decreased (↓) 11 16.92 
Decreased (↓↓) 1 1.53 
Decreased (↓↓↓) 1 1.53 
Nil 5 7.69 
 
 
 
Of these 65 patients only 23 patients (33.8%) had Icterus 
others were anicteric. 
  
 
Table 17a: Distribution of various biochemical parameters in the study population 
 
S.No Parameter Number (n) Percentage (%) 
1 
Hemoglobin (g/dl)  Mean: 9.08 and SD 0.91 
<8 4 6.15 
8-8.99 30 46.1 
9-9.99 28 43.07 
10-11 1 1.53 
>11 2 3.07 
2 
Platelet count 
In normal range 20 30.7 
Decreased (↓)> 1Lack 3 4.61 
Decreased (↓↓)       
50-1Lacks 
1 1.53 
Decreased 
(↓↓↓)<50,000  
41 63.07 
3 
Random blood sugar 
In Normal range 62 95.38 
Decreased (↓) 2 3.07 
Increased (↑) 1 1.53 
4 
Renal function test 
In normal range 61 93.84 
Elevated (↑)  3 4.61 
Elevated (↑↑) 1 1.53 
 
 
The mean hemoglobin  in this study group is 9-9.9 which 
is around 46% and 6.1% of this patients diagnosed with 
hemoglobin of <8gms/dl 
Of these 65 patient studied 41 patient had reduced platelet 
count of <50,000 and 1 patient had hypoglycemia around 6% 
associated with elevated renal function test. 
 
  
Table 17b: Distribution of various liver function test parameters in the study population 
 Parameter Number (n) Percentage (%) 
S11 
Total bilirubin (mg/dl) 
In normal range 22 33.8 
Elevated (↑)  38 58.4 
Elevated (↑↑) 4 6.15 
Elevated (↑↑↑) 1 1.53 
2 
InDirect bilirubin (mg/dl) 
In normal range 21 32.3 
Elevated (↑)  40 61.5 
Elevated (↑↑) 3 4.61 
Elevated (↑↑↑) 1 1.53 
3 
Direct bilirubin (mg/dl) 
In normal range 37 56.9 
Elevated (↑)  27 41.6 
Elevated (↑↑) 1 1.53 
4 
SGOT 
In normal range 52 80 
Elevated (↑)  11 16.92 
Elevated (↑↑) 2 3.08 
5 
SGPT 
In normal range 54 83.07 
Elevated (↑)  8 12.3 
Elevated (↑↑) 2 3.07 
Elevated (↑↑↑) 1 1.53 
6 
LDH 
In normal range 64 98.46 
elevated  1 1.53 
7 Bile salts and bile pigments 
 Present 2 3.07 
 Absent 63 96.92 
8 Bleeding time and clotting time 
 In normal range 58 89.23 
 Elevated (↑)  6 9.23 
 Elevated (↑↑) 1 1.53 
9 Prothrombin time and INR 
 In normal range 58 89.23 
 Elevated (↑↑) 7 10.76 
  
 
 
  
 
Table 18: Distribution of viral markers in the study population 
 
S.No 
Type of viral 
markers 
Number (n) Frequency (%) 
1 Negative 37 56.9 
2 HAV positive 1 1.53 
3 HBs AG positive 26 38.46 
4 HCV positive 1 1.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: TYPES OF VIRAL ETIOLOGIES 
 
Of these 28 viral Hepatitis 26 patients (86.6%) associated with Hepatitis B, 1 
Hepatitis C and 1 Hepatitis A virus positivity. 
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Table19:LEVEL OF INITIAL BILIRUBIN 
INITIAL BILIRUBIN TOTAL PERCENTAGE 
<5 31 47.7 
5-10 22 33.8 
10-15 10 15.4 
>15 2 3.1 
Maternal mortality and morbidity was directly related to the initial 
level of bilirubin . Initial serum bilirubin level of > 13 lead to 50% 
mortality. About 33.8% of women had an initial serum bilirubin level of 
about 5 – 10 mg / dl. 
Keeping the initial bilirubin level at admission as 10 mg/dl , the 
maternal outcome was poor and high mortality rate was seen when the 
bilirubin level exceeds 10 mg/dl. It is statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
LEVEL OF INITIAL BILIRUBIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: LEVEL OF INITIAL BILIRUBIN 
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Table 20: STATISTICAL SIGNIFICANCE OF INITIAL BILIRUBIN LEVEL 
 
. EXPIRED RECOVERED  TOTAL 
A (<10) 3 50 53 
B (>10) 5 7 12 
TOTAL 8 57 65 
 0.123 0.008  
 
 
Initial level of bilirubin >10 mg/dl is associated with high level 
of maternal mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 21: Frequency distribution of USG findings in the study population 
 
S.No 
Finding observed 
in USG 
Number (n) Frequency (%) 
1 ABRUPTION 1 1.53 
2 IUD 3 4.6 
3 IUGR 10 15.3 
4 Splenomagaly 1 1.53 
5 Normal findings 50 77.4 
 
During Antenatal scanning 15.3% of patients diagnosed to 
have IUGR babies,1 patient diagnosed as splenomegaly and 
77.4% had normal antenatal scan,1patient diagnosed with 
abruption and 3 patients (4.1%) diagnosed with IUD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 22: Maternal complications observed in the study population 
 
S.No Type of the complication 
Number 
(n) 
Frequency 
(%) 
1 ABRUPTION 1 1.5 
2 AKI 1 1.5 
3 ATONIC 8 10.7 
4 DIVC /HELLP 2 3.0 
5 HEP.ENC 4 6 
6 NIL 51 77.3 
 
 
The most common complication encountered in jaundice 
during periparturn is 10.7% is PPH. 
 
 
 
 
 
 
 
 
 
 
 
 Table 23: MATERNAL COMPLICATIONS 
MATERNAL 
COMPLICATIONS 
TOTAL 
HEPATIC 
ENCEPHALOPATHY 
4 
ARF 2 
ATONIC PPH 8 
ABRUPTION 1 
DIC 2 
 
 
 
Table 24:Description of maternal mortality outcome in the study population 
 
S.No Type of outcome in maternal mortality Number (n) 
Frequency 
(%) 
1 Discharged 56 86.2 
2 Maternal death 8 12.3 
3 Discharged against medical advice 1 1.5 
 
 
 
From our study group of 65, 56 patients (86.2%) were 
discharged in good condition,8 were expired, and 1paient 
discharged against medical advice. 
  
 
 
 
 
 
 
 
 
Table 25: BLOOD TRANSFUSIONS 
 
SI.No. Number of  
patients  
Number of packed 
cell 
Frequency(%) 
1 27 Nil 41.54 
2 13 1 20.0 
3 6 2 9.3 
4 7 3 10.77 
5 9 4 13.8 
6 3 >4 4.62 
 
According to this study 59.5% required blood 
transfusion,of these 20% patients transfused with 1unit only 
4% of patients had >4units of packed cell transfusion. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 11: BLOOD TRANSFUSIONS 
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Table 26:CAUSE OF DEATH 
 
CAUSE OF DEATH  Numbers PERCENTAGE 
HELLP 4 50 
AFLP 2 25 
VIRAL 
1 12.5 
AKI 1 12.5 
 
4 women expired. HELLP (50 %) was the cause in 4 out of 8 women who 
died. 2 from AFLP (25%), 1 AKI (12.5%), 1 death due to VIRAL (12.5%). 
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Figure 12:CAUSE OF DEATH 
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     Table 27:  COMPARISON OF NEONATAL OUTCOME. 
 
1 
Term of 
the baby 
Preterm 15 (23.7%) 0 (0%) 
p<0.0009* 
OR: 25.8 
CI : 1.4 to 
461.4 
 
Term 44 (37.2%) 22 (33.8%) 
2 
Status of 
the baby 
Dead 5 (7.69%) 0 (0%) P=0.155 (NS) 
OR: 6.6 
CI: 0.3 to 125.2 Alive 54 (56.9%) 22 (33.8%) 
3 
NICU 
admission 
Yes 15 (6.2%) 1 (1.53%) P=0.65(NS) 
OR: 2.2 
CI:0.23 to21.09 No 39(58.4%) 21 (32.3%) 
 
Data are expressed as absolute numbers with percentage. 
Fisher’s exact test was used to test the statistical difference 
between the proportions. * indicates p value less than 0.05 and 
considered statistically significant. 
 
 
 
 
 
 
 
 
  
 
 
 
DISCUSSION 
 
 
 
 
 DISCUSSION 
 
The incidence of jaundice in India varies from 0.4 to 
0.9/1000 deliveries. According to 0ur study incidence is 
0.4/1OOO deliveries, which is in equal with Kamalajayaram 
and Rama Devi et al46reported 0.4/1000 incidence. Singh et 
al45reported 1.03/1000 incidence. 
COMPARISON OF INCIDENCE 
Previous studies Incidence 
Meena.N.Satia et al 0.81% 
Brijesh J patel et al 0.49% 
Pranithi mitta et al 0.31% 
Nagaria Tripti et al 0.55% 
Jayanthi et al 0.29% 
Our study 0.4% 
 
 
 
 COMPARISON OF AGE 
Previous studies AGE 
Meena et al 25-29(45.4%) 
Swati et al 21-25(66.66%) 
Brijesh et al 20-24(51%) 
Pranithi mitta et al 25-29(38.09%) 
Our study 21-25(56.93%) 
 
In our study, most of the patients were in the age group of 
21-25 years, which is comparable with Swati et al.  In the study 
done by Meena et al,most of the patients were in the age group 
of 25-29 yrs. In the study done by  Brijesh et al, most of the 
patients were in the age group of  20-24 years.In the study done 
by Pranithi mitta et al , most of the patients were in the age 
group of 21-25 years of age 
 
 
 COMPARISON OF PARITY 
Previous studies Primipara Multipara 
Meena et al 49% 47.3% 
Swati et al 66.60% 33.40% 
Pranithi mitta et al 38.09% 61.9% 
Our study  61.50% 38.5% 
 
           In our study,61.50%  were primipara.In the study 
done by Meena et al,  49% were primipara.In the study done by 
Swati et al, 66.6% were primipara.In the study done by Pranithi 
mitta et al,61.9% were multipara 
 
 
 
 
 
 
 COMPARISON OF BOOKING STATUS 
Previous studies Unbooked 
Swati et al 93.3% 
Brijesh et al 66% 
Our study  3.1% 
 
In our study only 3.1% were unbooked. In the study done 
by Swati et al, 93.3% were unbooked. In the study done by 
Brijesh et al, 66% were unbooked. 
 
 
 
 
 
 
 
 COMPARISON OF CAUSE OF JAUNDICE 
Previous 
studies 
HELLP  AFLP Viral Cholestasis 
 
Portal 
HT 
Hemolytic 
Meena et al 0 0 62% 23.6% 0 0 
Swati et al 46.3% 0 46.7% 6.7% 0% 0% 
Brijesh et al 18.3% 0 44.8% 22.4% 0 10.2% 
Krishnamoort
hy et al 
13.7% 0 50.98% 0 7.84% 0 
According to 
this study 
26.6% 3.1% 43.1% 1.53% 0 1.53% 
 
In our study,viral hepatitis is the commonest cause of 
jaundice.Also in all the studies done by   Meena et al  , Swati et 
al,  Brijesh et al and Krishnamoorthy et alviral hepatitis  is the 
commonest cause of jaundice 
 
 
 
 
  
COMPARISON OF DELIVERIES 
 
In our study, most of the patients were delivered by 
caesarean section. In all  the other  studies  by Meena et al, 
Swati et al , Brijesh patel et al  and Pranithi mitta et al  most of 
the patients were delivered by labour Natural 
 
 
 
 
Previous studies Vaginal Delivery Caesarean Delivery 
Meena et al 81% 19% 
Swati et al 100% 0% 
Brijesh patel et al 82.3% 17.7% 
Pranithi mitta et al 69.2% 30.8% 
Our study 49.24% 50.76% 
  
COMPARISON OF BILIRRUBIN ON ADMISSION 
Previous studies >10(mg/dl) 
Brijesh et al 21.4% 
Pranithi mitta et al 14.3% 
Krishnamoorthy et al 7.84% 
Our study 15.5% 
 
In our study, 15.5% had bilirubin >10 mg/dl at the time of 
admission, which is comparable with Pranithi mitta et al study. 
In the study done by Brijesh et al,21.4% had bilirubin >10 
mg/dl at the time of admission.In the study done by Pranithi 
mitta et al, 14.3% had bilirubin >10 mg/dl at the time of 
admission. In the study done by Krishnamoorthy et al, 7.84% 
had bilirubin >10 mg/dl at the time of admission. 
 
 
 COMPARISON OF COMPLICATIONS 
Previous 
studies 
Multi 
Organ 
Failure 
Hepatic 
encepha
lopathy 
Renal 
failure 
PPH DIVC Hepatic 
failure 
Meena et al 9% 20% 11% 22% 44% 24% 
Swati et al 13.3% 3.3% 13.3% 60% 20% 0 
Brijesh et al 0 18.3% 10.2% 8.1% 26.5% 0 
Pranithi mitta 
et al 
0 0 7.14% 4.76
% 
11.9% 0 
Krishnamoorth
y et al 
0 7.87% 3.9% 9.8% 5.8 0 
Our study 0 6.1% 12.5% 12% 3% 0 
In our study the incidence of hepatic encephalopathy was 
6.1%. In the study done by meena et al the s incidence was 
20%,in Swati et al the incidence of hepatic encephalopathy was 
3.3% ,in Brijesh et al the incidence of hepatic encephalopathy 
was 18.3%.the incidence of hepatic encephalopathy  was very 
high in our study.on comparing with other studies the incidence 
of PPH is comparable with Krishnamoorthy et al (22%). 
 COMPARISON OF MATERNAL DEATHS 
 
In our study ,Percentage of deaths due to jaundice 
amongst total maternal deaths is 12.03%.it is comparable to 
other studies like Kamalajayaram et al,46 Roychowdhary et 
al50and  Rao et al 49 . 
In the study done by Trivedi et al,52 Percentage of deaths 
due to jaundice amongst total maternal deaths is 29.3% 
 
 
Previous studies Year Percentage of deaths due 
to jaundice amongst total 
maternal deaths 
Kamalajayaram and Rama Devi 
1988 12.4 
Rao and Rudra 2001 15.8 
Roychowdhary et al 1990 13.37 
Bera and Sengupta 1992 19.9 
Sapre and Joshi 1999 04.99 
Trivedi et al 2003 29.3 
According to our study 2017 12.03 
 COMPARISON OF CAUSES OF MATERNAL DEATHS 
 
In our study, viral hepatitis is the commonest cause for 
jaundice. It is comparable with studies done by Meena et al  , 
Swati et al,  Brijesh et al and Krishnamoorthyet al     viral 
hepatitis  is the commonest cause of jaundice. 
HELLP syndrome is the most common cause for jaundice 
and associated with high mortality and morbidity.comparing 
with other studies the incidence of HELLP in our study 26.6%. 
 
Previous 
studies 
 
Cause of Maternal Death 
HELLP AKI AFLP Viral  Drug 
induced 
Choles
tasis 
 
Pre 
Eclampsia 
PHT 
Meena et al 8% 0 0 59% 8% 0 0 17% 
Swati et al 0 0 0 100% 0 0 0 0 
Pranithi 
mitta et al 
21.4% 0 2.38% 52.3% 0 14.2% 0 0 
Krishnomo
orthy et al 
25% 0 50% 0 0 0 0 25% 
Our study 50% 12.5% 25% 12.5% 0 0 0 0 
 COMPARISON OF FETAL MATURITY       
Previous studies Preterm Term 
Meena 32-37 wks(43.6%) 31% 
Swati 26.7% 73.3% 
Brijesh 68.8% 31.1% 
Pranithi mitta  35% 62.2% 
Our study 24.3% 70.9% 
 
In our study the fetal maturity is 70.9% which is equal 
with   study done by Swati et al and Pranithi mitta et al majority 
of babies were born at or after term.In other studies by Meena et 
al and Brijesh et al,majority of babies were born preterm.  
 
 
 
 
 
 
 
 COMPARISON OF NEONATAL OUTCOME  
 
Comparing with other studies the incidence of  live 
births(91.5%)which is comparable with Brijesh et al  study 
which was (90.35%),incidence of low birth weight is comparable 
with our study is meena et al study which is (50%) ,in our study 
its (30%,incidence of intrauterine fetal death in our study is 
(7.69%),which is comparable withSwati et al study which 
Previous 
studies 
Live 
Birth 
LBW IUGR 
 
IUFD Preterm MSAF NICU 
Admission 
Meena et al 67% 50% 50% 22% 43.6% 28% 50% 
Swathi et al 0 0 6.7% 13.5% 26.7% 40% 0 
Brijesh et al 90.3% 87.7% 0 16.2% 68.8% 32.2 54.8% 
Pranitha 
mitta et al  
79.4% 85.7% 0 20.55
% 
35% 0 0 
Krishnamoo
rthy t al  
73.3% 0 0 26.6% 35% 0 0 
Our study 91.5% 30% 15.3% 7.69% 23.7% 3.3% 27% 
 is(13.5%).The incidence of preterm deliveries were comparable 
wth Pranithi mitta study, in our study the incidence of pre term 
is 23.7%, and  in swathi et al the incidence is26.7%. of these 
27% of babies from our study were admitted  NICU. which is 
very low with other studies. 
According to our study percentage of maternal deaths due 
to jaundice is 12.3 % which is nearly comparable with the study 
conducted by Sapre and Joshi. 
HELLP,AKI, AFLP and VIRAL HEPATITIS were responsible for 
the deaths. According to our study HELLP (50%) was the cause 
in 4 out of 8 women who died , two women died of AFLP,one 
women died of VIRAL HEPATITIS, one women died of AKI . 
Various studies also report jaundice as one of the major 
indirect cause of maternal death, responsible for 5 to 30% of all 
maternal deaths 46,48-52. Maternal deaths were directly 
proportional to the level of the serum bilirubin. Trivedi et 
al52also observed the same. According to this study the initial 
bilirubin level at admission > 10 is associated with poor 
 maternal outcome and high maternal mortality. Kamalajayaram 
and Rama Devi 46 reported 33.3% maternal mortality and Singh 
et al45reported 10%. 
 
 
 
 
 
 
 
 
  
 
 
 
SUMMARY 
 
 
 
 
 
 SUMMARY 
The study was conducted in 65 with jaundice complicating 
pregnancy. The most common age group affected by this disease 
are 21-25 years and its mainly found in third trimester of 
pregnancy.  
Primi gravidas are most commonly affected by this disease. 
96% of the patients were booked and immunized patients. The 
incidence of LSCS are more compared with vaginal deliveries, 
most commonest cause found in this study is viral hepatitis 
which is about 43.1%,1death due to hepatitis B occurred in this 
study.  
In 59 deliveries, 15 were preterm, 3 were IUD and 2 death 
were during post natal period. Of this study male babies were 
50.8% and  female babies were 49.2% . Most common cause for 
jaundice in this study is HELLP syndrome, AFLP, AKI, and one 
death due to viral hepatitis. 
The present study shows higher incidence of maternal 
mortality is very high in jaundice and nearly 75% patients 
 requires blood transfusion. DIC, Hepatic encephalopathy are 
the most common complications encountered in this study. 
 
 
 
 
 
 
 
 
  
 
 
 
CONCLUSION 
 
 
 
 
 CONCLUSION 
Jaundice in pregnancy is associated with high maternal 
mortality and perintalmortality rates. 
Viral hepatitis is the leading cause of jaundice according to 
our study withhepatitis B being the predominant virus. Hepatic 
encephalopathy and acute kidney injury are the two important 
maternal complications. HELLP is thecommon cause of death 
according to our study. 
According to our study the initial bilirubin level at 
admission > 10 isassociated with very poor maternal outcome 
and high maternal mortality. 
The factors responsible for a high maternal mortality in 
our country may bedelay in seeking medical advice,poor 
nutrition hygiene, prevalence of anemia, and delay in referral to 
the hospital. Many of the patients when brought to thetertiary 
health care system are already in moribund condition and often, 
do not 
respond to treatment. 
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ICU CARE: 
 
MATERNAL OUTCOME: 
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CONSENT FORM 
 
 
 
 Study detail: A study on “MATERNAL AND FETAL OUTCOME IN JAUNDICE 
COMPLICATING PREGNANCY” 
Study Centre:  Department of Obstetrics and Gynaecology, Thanjavur 
Medical College, Thanjavur. 
I confirm thatI have read and understood the information Sheet for 
the above study. I have had the opportunity to ask questions and all my 
questions and doubt have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time, without giving any reason, without 
my legal rights being effected. 
I understand that the clinical study personnel, the Ethics Committee 
and the Regulatory Authorities will not need my permission to look at my 
health records both in respect to the current study and any further 
research that may be conducted in relation to in, even if I withdraw from 
the study. I agree to this access. However, I Understand that my identity 
will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use 
of any data or results arise from this study. 
I agree to take part in the above study and to comply with the 
instruction given during the study and faithfully co-operate with the study 
team and to immediately inform the study if I suffer from any deterioration 
in my heath of well being or any unexpected or unusual symptoms. 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including haematological, biochemical and 
radiological tests. 
I hereby consent to participate in this study. 
Signature/Thumb 
impression:………………….Place………………..Date…………… 
of the patient 
Patient’s Name, Address and Phone no: ………………………… 
Name of the Investigation: …………………………………………. 
Sig of the Investigator:……………………Place……………….Date………… 
Institution:…………………….. 
Signature of the Relative/ Guardian: ………………………………………… 
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KEEY TO MASTER CHART 
 
GA: Gestational age 
HT: Hypertension 
GDM: Gestational diabetes mellitus 
HB: Hemoglobin 
PS: Peripheral smear 
IUD: Intrauterine death 
DIC: Disseminated intravascular coagulation 
BS/BP: Bile salts /bile pigments 
NS: Neutrophilic shift 
IUGR: Intrauterine growth retardaion 
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